Gastric Cancer Drug Market in China 2021
![](/report_cover/11753/gastric-cancer-drug-market-in-china-2021_en.gif)
The gastric cancer drug market in China in terms of revenue is set to grow by US$ 4 billion during 2021-2027, growing at a compound annual growth rate (CAGR) of 10.3% during the forecast period, according to data and analytics company StrategyHelix.
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for gastric cancer drug. The China gastric cancer drug market is segmented on the basis of type. By type, it is categorized into cisplatin, fluorouracil, paclitaxel, targeted drugs, and others.
The report has profiled some of the key players of the market such as Chongqing Taihao Pharmaceutical Co. Ltd., Eli Lilly and Company, Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Qilu Pharmaceutical Co. Ltd., Roche Holding AG.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the gastric cancer drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: cisplatin, fluorouracil, paclitaxel, targeted drugs, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China gastric cancer drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the gastric cancer drug market in China looks like
Identify the competitive landscape and window of opportunity
The report provides up-to-date market size data for period 2017-2020 and forecast to 2027 covering key market aspects like sales value for gastric cancer drug. The China gastric cancer drug market is segmented on the basis of type. By type, it is categorized into cisplatin, fluorouracil, paclitaxel, targeted drugs, and others.
The report has profiled some of the key players of the market such as Chongqing Taihao Pharmaceutical Co. Ltd., Eli Lilly and Company, Jiangsu Chia Tai-Tianqing Pharmaceutical Co. Ltd., Jiangsu Hengrui Medicine Co. Ltd., Qilu Pharmaceutical Co. Ltd., Roche Holding AG.
The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the gastric cancer drug market to help drive informed decision making for industry executives, policy makers, academic, and analysts.
Report Scope
Type: cisplatin, fluorouracil, paclitaxel, targeted drugs, and others
Years Considered: this report covers the period 2017 to 2027
Key Benefits for Stakeholders
Get a comprehensive picture of the China gastric cancer drug market
Pinpoint growth sectors and trends for investment
Understand what the future of the gastric cancer drug market in China looks like
Identify the competitive landscape and window of opportunity
1. MARKET DEFINITION
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. GASTRIC CANCER DRUG MARKET BY TYPE
4.1 Cisplatin
4.2 Fluorouracil
4.3 Paclitaxel
4.4 Targeted Drugs
4.5 Others
5. COMPANY PROFILES
5.1 Chongqing Taihao Pharmaceutical Co., Ltd.
5.2 Eli Lilly and Company
5.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd.
5.4 Jiangsu Hengrui Medicine Co., Ltd.
5.5 Qilu Pharmaceutical Co., Ltd.
5.6 Roche Holding AG
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer
2. RESEARCH METHODOLOGY
3. MARKET DATA & OUTLOOK
3.1 Market Value
3.2 Market Value Forecast
4. GASTRIC CANCER DRUG MARKET BY TYPE
4.1 Cisplatin
4.2 Fluorouracil
4.3 Paclitaxel
4.4 Targeted Drugs
4.5 Others
5. COMPANY PROFILES
5.1 Chongqing Taihao Pharmaceutical Co., Ltd.
5.2 Eli Lilly and Company
5.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Co., Ltd.
5.4 Jiangsu Hengrui Medicine Co., Ltd.
5.5 Qilu Pharmaceutical Co., Ltd.
5.6 Roche Holding AG
6. APPENDIX
6.1 About StrategyHelix
6.2 Disclaimer